OCX
- OncoCyte Corporation
()
Overview
Company Summary
OncoCyte Corporation, also known as OCX, is a biotechnology company primarily focused on the development and commercialization of novel diagnostic tests for the early detection of various types of cancer. The company's mission is to improve patient outcomes and reduce healthcare costs associated with cancer diagnosis and treatment.
OncoCyte's core expertise lies in the field of molecular diagnostics, which involves the analysis of genetic information in cells and tissues to diagnose diseases. The company has developed a unique platform called the DetermaRx�, which utilizes advanced molecular technologies to detect the presence of cancer in its early stages.
One of OncoCyte's key products is the DetermaVu� Lung Cancer Assay, which is designed to aid in the early detection of lung cancer. This test utilizes a blood-based biomarker panel that can identify lung cancer at an earlier stage than conventional methods such as imaging or tissue biopsies. By detecting lung cancer earlier, patients have a higher chance of successful treatment and improved survival rates.
In addition to lung cancer, OncoCyte is also dedicated to the development of diagnostic tests for other types of cancer, including breast, bladder, and prostate cancer. The company is continuously investing in research and development efforts to expand its diagnostic capabilities and target additional cancer types.
OncoCyte collaborates with leading academic institutions, research centers, and medical professionals to conduct clinical studies and validate the effectiveness of their diagnostic tests. This collaborative approach ensures that their products meet the highest standards of accuracy and reliability.
Overall, OncoCyte Corporation plays a critical role in the fight against cancer by providing innovative and accurate diagnostic tools that enable healthcare professionals to detect cancer at an early stage, improving patient outcomes and potentially saving lives.